Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Nitriles Stories

2012-12-09 16:20:28

- 68% transfusion independence response rate and 37% durable spleen response rate - MISSISSAUGA, ON, Dec. 9, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported updated results from the 166 patient Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results were presented this afternoon in an oral session at the 54(th) Annual Meeting of the American Society of Hematology underway in Atlanta, Georgia. --...

2012-12-03 20:57:17

Prostate cancer drug shows promise in triple-negative and estrogen-positive breast cancer Breast cancers are defined by their drivers — estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options — this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative. A decade ago,...

2012-12-03 16:24:33

MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys PTE Ltd., a company based in Singapore, for undisclosed consideration including an immediate US$2 million payment. CIMYM was a joint venture subsidiary 80% owned by YM BioSciences and 20% owned by CIMAB S.A. (representing Centro de Inmunología Molecular, Cuba). CIMAB S.A. has reported it...

2012-11-20 16:29:23

MISSISSAUGA, ON, Nov. 20, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today announced that Kapil Dhingra has been elected by shareholders to the Company's Board of Directors at YM's Annual Meeting of Shareholders held this afternoon. Dr. Dhingra has 25 years of experience in oncology clinical research and drug development. Previously, Dr. Dhingra held the position of Vice President,...

2012-11-05 12:26:04

MISSISSAUGA, ON, Nov. 5, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported interim results from the Phase I/II study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, which were included in an abstract submitted to the American Society of Hematology in August 2012. Updated results will be presented in an Oral Session at the 2012 Annual...

2012-10-11 07:27:59

MISSISSAUGA, ON, Oct. 11, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today announced that the results of its Phase I/II Study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, have been selected by the ASH Program Committee for presentation in an Oral Session at the 2012 Annual Meeting of the American Society of Hematology to be held in...

2012-09-21 02:23:16

- Completed dosing for 166 patient CYT387 Phase I/II nine-month trial - - Completed enrolment of 61 patient CYT387 Phase II BID trial - MISSISSAUGA, ON, Sept. 21, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported operational and financial results for its 2012 fiscal year, ended June 30, 2012. "We made significant progress with CYT387 during Fiscal 2012, highlighted by our...

2012-09-13 06:30:16

MUMBAI, India and BALTIMORE, Maryland, September 13, 2012 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Escitalopram Tablets (Escitalopram oxalate) 5 mg, 10 mg, and 20 mg, from the United States Food and Drugs Administration (FDA) to market a generic version of Forest Laboratories, Inc.'s (Forest) Lexapro Tablets, 5 mg, 10 mg, and 20 mg. Lupin's...

2012-08-28 10:25:40

New research published in BioMed Central's open access journal BMC Medicine reassessing clinical data from trials, which investigate ways of treating side effects of therapy for prostate cancer, finds that tamoxifen, an anti-estrogen used to treat breast cancer, is also able to suppress gynecomastia and breast pain in men. Prostate cancer is one of the most common cancers in men and early treatment is usually very successful. Androgen-suppression therapy is often used to slow down...

134136911
2012-06-02 07:20:53

A new study, published in a recent edition of the journal Menopause, has discovered that combining massage with aromatherapy can be an effective way in reducing the symptoms of menopause. The study, which was conducted by researchers at Tehran University of Medical Sciences and is included in the April 30 of the journal, looked at treatments received by 90 women who entered a "menopausal clinic" at a women's hospital in the Iranian capital, Reuters reporter Amy Norton wrote on Friday....